KR102217834B1 - Composition for Preventing or Treating Obesity Comprising Heat-killed Lactic Acid Bacteria from Kefir and Grape Seed Flour - Google Patents

Abstract

The present invention relates to a composition for preventing or treating obesity comprising grape seed powder and kefir-derived lactic acid bacteria. In the composition comprising the kefir-derived lactic acid bacteria dead cells and grape seed powder according to the present invention, the grape seed powder acts as a prebiotic, and the complex cells of the lactic acid bacteria dead cells isolated from the kefir act as probiotics, thereby preventing or treating obesity. . The composition of the present invention may be ingested in the form of a functional food or pharmaceutical composition to exert effects such as weight loss, fat cell weight and size reduction, cholesterol level reduction, and reduction in fat-forming gene expression.

Description

Composition for preventing or treating obesity containing dead cells of kefir-derived lactic acid bacteria and grape seed powder {Composition for Preventing or Treating Obesity Comprising Heat-killed Lactic Acid Bacteria from Kefir and Grape Seed Flour}

The present invention relates to functional foods and pharmaceutical compositions for improving, preventing or treating obesity, including dead cells of kefir-derived lactic acid bacteria and grape seed powder.

Obesity, a metabolic disorder caused by an imbalance between food intake and energy expenditure, is one of the most common and serious global health problems. Obesity is considered an important risk factor for a variety of chronic diseases, including high blood pressure, cardiovascular disease, type 2 diabetes, respiratory disease and cancer, which can incur enormous medical costs for both developed and developing countries.

Various approaches have been developed to treat obesity, but these treatments have been reported to have side effects such as increased blood pressure, liver failure, pancreatitis, headache, dry mouth, and hypermenorrhea. For this reason, natural products that can treat obesity are expected as safer and more effective anti-obesity treatments.

Recently, many studies have highlighted the potential of probiotics as natural anti-obesity treatments. Probiotics refer to the intestinal flora that is beneficial to health, that is, living microorganisms, or live fungi, that provide benefits to the health of the host. In general, probiotics are consumed as part of fermented foods such as yogurt or as dietary supplements. Microorganisms known as probiotics include lactic acid bacteria (LAB), bifidobacteria, and Bacillus. Some of the probiotics are known to have therapeutic effects on obesity, insulin resistance, and non-alcoholic fatty liver.

Kefir is a kind of fermented milk derived from the mountainous regions of the Caucasus, and it is a popular drink that Tibetan monks drink for health. Constituent nutrients of kefir include proteins and polysaccharides, and they evenly contain vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin D, vitamin K2, folic acid, nicotinic acid and calcium, iron, and iodine. Such kefir is a yogurt-like beverage obtained by fermenting milk using a fungus called kefir grain (also referred to as kefir granule bacteria), which is a complex of lactic acid bacteria and yeast, as an initiator.

Kefir contains various microorganisms including lactic acid bacteria ( Lactobacillus, Lactococcus, Leuconostoc, Acetobacter , and Streptococcus species), acetic acid bacteria and yeast ( Saccharomyces, Kluyveromyces, Torula and Candida species). Kefir has been proven to have anti-mutagenic, cholesterol-lowering, antimicrobial, immune-modulating and anti-inflammatory effects, but it has been specifically for the anti-obesity of kefir and inactivated dead cell lactic acid bacteria and yeasts inactivated by heat treatment. Nothing is known.

In general, functional foods containing probiotics can be divided into live bacteria or dead bacteria. When consumed as live bacteria, they are usually sold in the form of freeze-dried powder or fermented milk containing live bacteria. In the case of dead bacteria, physiological activity is hardly revealed compared to live bacteria, and it is consumed as a concept of prebiotics that promote growth as food for intestinal lactic acid bacteria.

In the case of such a conventional probiotic material, it is difficult to apply it in various processing forms other than powder or fermented milk, as it can be killed in processing such as sterilization in order to contain it in processed foods in a state of living bacteria to maintain physiological activity. It is known that the physiological activity of the dead cells has not been found to be contained as dead cells, and is known to be less active than the live cells, and it is still difficult to be applied to the field of food or medicine.

As a patent in the field of food or medicine using dead cells, a composition for preventing, treating or improving constipation containing the plant lactic acid bacteria Lactobacillus plantarum PMO08 dead cells as an active ingredient in Korean Patent Publication No. 10-1472190 It has been disclosed, and Korean Patent Publication No. 10-1369219 discloses an antibacterial lactic acid bacteria dead cell and a method for producing the same.

In a similar concept to probiotics, prebiotics are indigestible ingredients that help the growth of beneficial bacteria in the intestine, and they refer to substances that help improve the intestinal environment by becoming a nutrient source of probiotics. In order for any food ingredient to be used as a prebiotic that is used by useful microorganisms in the large intestine to promote the growth or activity of microorganisms, thereby exhibiting a good effect on host health, it must not be digested or absorbed in the upper part of the gastrointestinal tract It should be able to selectively activate useful bacteria and suppress harmful bacteria such as pathogens.

On the other hand, grapes contain a lot of resveratrol, a polyphenol-based antioxidant found in plants, and resveratrol has antibacterial, anticancer, antiviral, antiallergic, and anti-inflammatory effects, and is a powerful antioxidant. As a substance with an active function, it is contained in a large amount in grape by-products such as peels, seeds, and pine branches, so if the grape by-products are discarded as they are, the useful ingredients contained in the agricultural products will be lost as well as environmental pollution. Research to increase the utility value of the company is actively being conducted.

The present inventors have completed the present invention by confirming that the dead cells of kefir-derived lactic acid bacteria and grape seed powder are effective in preventing or treating obesity by acting as probiotics and prebiotics, respectively.

An object of the present invention for solving such a problem is to provide a food for improving obesity, including dead cells of kefir-derived lactic acid bacteria and grape seed powder.

Another object of the present invention is to provide a pharmaceutical composition for preventing or treating obesity, including dead cells of kefir-derived lactic acid bacteria and grape seed powder.

In order to achieve the above object, the present invention provides a functional food for improving obesity, including kefir-derived lactic acid bacteria and grape seed powder as an active ingredient.

In the present invention, the kefir-derived lactic acid bacteria may be Leuconostoc mesenteroides , Lactobacillus kefiri or a complex cell thereof, preferably Leuconostoc mesenteroides LCM4 ( leuconostoc mesenteroides LCM4, accession number: KCCM12117P) and Lactobacillus kefiri DH5 ( Lactobacillus kefiri DH5, accession number: KCCM11837P) may be a complex cell.

In the present invention, the dead cells may be killed by heat treatment at 80 ℃ or higher derived from kefir lactic acid bacteria.

In the present invention, the dead cells may be in the form of a suspension obtained by crushing the kefir-derived lactic acid bacteria after heat treatment and death.

In the present invention, the dead cells may be an aqueous fraction of a suspension obtained by crushing kefir-derived lactic acid bacteria after heat treatment and death.

In the present invention, the complex cells may contain Leukonostock mecenteroides LCM4 and Lactobacillus kepiri DH5 in a concentration ratio of 5:1 to 1:5.

In the present invention, the kefir-derived lactic acid bacteria dead cells may be included as 0.1x10 ⁸ to 20x10 ⁸ lactic acid bacteria / gram grape seed powder.

In the present invention, the grape seed powder may be a wine production by-product, and may be prepared from grapes of Chardonnay (Chardonnay) varieties.

In the present invention, the functional food may be characterized in that it suppresses the expression of adipocyte-forming genes.

In the present invention, the functional food may be a fermented food.

The present invention also provides a pharmaceutical composition for preventing or treating obesity, comprising kefir-derived lactic acid bacteria and grape seed powder as active ingredients.

In the composition comprising the kefir-derived lactic acid bacteria dead cells and grape seed powder according to the present invention, the grape seed powder acts as a prebiotic, and the complex cells of the lactic acid bacteria dead cells isolated from the kefir act as probiotics, thereby preventing or treating obesity. . The composition of the present invention can be ingested in the form of a functional food or pharmaceutical composition to exert effects such as weight loss, fat cell weight and size reduction, cholesterol level reduction, and reduction in fat-forming gene expression.

Figure 1 (a) is a graph showing the total energy intake of mice according to the type of diet.
1(b) is a graph showing the amount of weight gain in mice according to diet type.
2 is a graph showing the weight of adipose tissues of experimental mice according to the type of diet.
3 shows images of adipocytes of experimental mice according to diet types.
4 is a graph showing the TG and TC values of the experimental mice according to the type of diet.
5 is a graph showing the expression level of FASN gene in experimental mice according to diet type.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by an expert skilled in the art to which the present invention belongs. In general, the nomenclature used in this specification is well known and commonly used in the art.

The present invention relates to a composition for improving obesity containing dead cells of kefir-derived lactic acid bacteria and grape seed powder as an active ingredient.

In the present invention, "probiotics" refers to strains that have a beneficial effect on the intestinal environment when ingested and reach the intestine.

In the present invention, "Prebiotics" refers to substances that help improve the intestinal environment by serving as a nutrient source for probiotics as an indigestible component that helps the growth of beneficial bacteria in the intestine.

In the present invention, kefir is a kind of fermented milk derived from mountainous Caucasus, and kefir refers to a yogurt-like beverage obtained by fermenting milk using a species called kefir grain, which is a complex of lactic acid bacteria and yeast, as an initiator. .

In the present invention, the term "dead cells" is the opposite concept of live cells and refers to a form in which the growth of the bacteria is prevented by heat treatment or the like obtained through fermentation. Dead cells may include cytoplasm, cell wall, antibacterial active substances such as bacteriocin, polysaccharides, organic acids, and the like.

Dead cell products have high stability compared to live cells. In particular, it has the advantage that it has excellent heat resistance and high stability against the external environment, so it is easier to store and extend the shelf life than existing live bacteria products. In addition, as the regulations on the use of antibiotics are strengthening, the marketability and growth potential are very high, as there are many companies that have been able to use them as substitutes and are still in full swing in the production of dead cells.

In the present invention, it was found that the lactic acid bacteria isolated from kefir exhibit anti-obesity activity even when ingested in the form of dead cells inactivated by heat-killed. Therefore, there is a possibility that it can be applied in various processing forms without losing anti-obesity activity even in the sterilization process of processed foods.

In the present invention, kefir-derived lactic acid bacteria that can be applied as dead cells having anti-obesity activity may be Lactobacillus kefiri , leuconostoc mesenteroides , or a complex cell thereof.

Preferably, the kefir-derived lactic acid bacteria usable in the present invention is Lactobacillus kefiri DH5 ( Lactobacillus kefiri DH5, deposit institution: Korea Microorganism Conservation Center, accession number: KCCM11837P, accession date: April 29, 2016), Leukono It may be a stock mesenteroides LCM4 ( leuconostoc mesenteroides LCM4, deposit institution: Korea Microorganism Conservation Center, accession number: KCCM12117P, accession date: September 21, 2017), or a complex cell thereof. Most preferably, it is suitable for the prevention or treatment of obesity to use complex cells of Lactobacillus kepiri DH5 and Leukonostock mecenteroides LCM4.

The complex cells may be used by mixing Lactobacillus kepiri DH5 and Leukonostock mecenteroides LCM4 at a concentration of 10:1 to 1:10, preferably mixed at a concentration of 5:1 to 1:5. I can.

The dead cells of kefir-derived lactic acid bacteria according to the present invention may be killed by heat treatment at 80° C. or higher of kefir-derived lactic acid bacteria. Alternatively, the dead cells may be in the form of a suspension obtained by crushing the kefir-derived lactic acid bacteria by heat treatment. Alternatively, the dead cells may be in the form of an aqueous fraction of a suspension obtained by crushing kefir-derived lactic acid bacteria after heat treatment and killing.

The present inventors also confirmed that the grape seed powder acts as prebiotics having a beneficial effect on the probiotic activity of dead cells of kefir-derived lactic acid bacteria.

There is no particular limitation on the variety, production area, or harvest time of grapes used in the present invention, but it is most preferable to use Chardonnay grapes.

The grape seed powder of the present invention may be produced from by-products generated during the manufacturing process of beverages or alcoholic beverages using grapes. Preferably, the grape seed powder may be produced from by-products generated during the manufacturing process of wine or wine.

Here, "by-product" refers to the remaining products excluding wine or wine distillate produced in a distillation process after crushing and fermentation using grapes as a raw material.

Typically, wine or by-products generated during wine production are being discarded. However, such waste amounts to about 40% of the raw grapes, which is a huge economic loss. According to the present invention, since by-products generated during wine production can be utilized as prebiotics, there is a great advantage in environmental and economic terms.

"Grape seed flour" (GSF) according to an embodiment of the present invention separates grape seeds from by-products remaining after producing wine, dried, and then from grape seeds using a "cooling press", "heat press" technique, etc. It can be produced by extracting the oil and then grinding it into a powder. Separation, drying, compression, and pulverization of the grape seed powder may be performed in various forms by conventionally known techniques.

The particle size of the grape seed powder can be variously adjusted according to the grinding environment, and sieving can be added to produce a powder with smaller particles. The particle size of grape seed powder can be adjusted according to the purpose and use of food and medicine.

In the present invention, it was found that the ingestion of dead cells of grape seed powder and kefir-derived lactic acid bacteria exhibits excellent effects in improving obesity due to a high fat diet. In particular, it was confirmed that grape seed powder and kefir-derived lactic acid bacteria dead cells exert a synergistic effect when ingested together, and show a remarkable effect that is difficult to predict from the case of ingesting them respectively.

Specifically, when ingesting grape seed powder and kefir-derived lactic acid bacteria dead cells together, weight gain and fat cell weight increase due to a high fat diet can be suppressed. In one embodiment of the present invention, when the obese mice induced by a high fat diet are ingested with grape seed powder and kefir-derived lactic acid bacteria dead cells together with a high fat diet, weight gain and an increase in fat cell weight can be significantly reduced. Confirmed.

In addition, the mice that ingested the grape seed powder and kefir-derived lactic acid bacteria dead cells of the present invention further reduced the total cholesterol level compared to the mice that ingested them respectively, and that the expression of genetic agents involved in fat production can also be reduced. Confirmed.

The kefir four-derived lactic acid bacterium cells is based on the weight of the grape seed powder, 0.1x10 ⁸ to 20x10 ⁸ preferably mixed with lactic acid / grape seed powder, and gram, 1.0x10 ⁸ to 10x10 ⁸ lactic acid bacteria and / grape seed powder gram is more preferred, from about It is most preferable to mix 8x10 ⁸ lactic acid bacteria/grams of grape seed powder.

The composition containing the grape seed powder and kefir-derived lactic acid bacteria dead cells of the present invention can be utilized as a functional food for improving obesity.

The functional food is preferably a fermented food, but is not limited thereto. For example, functional foods may be beverages, gums, teas, vitamin complexes, dietary supplements, and more specifically, dairy products, confectionery, seasonings, beverages and drinks, snacks, candies, jellies, ice cream and frozen desserts. , Breakfast cereals, nutrition bars, snack bars chocolate products, processed foods, grain products and pasta, soups, sauces and dressings, confectionery products, oil and fat products, dairy drinks and milk beverages, tea, soy milk and soy milk products (soy dairy-like product), frozen foods, cooked foods and alternative foods, meat products, cheese, yogurt, bread and rolls, cakes, cookies, and may be any one selected from the group consisting of crackers.

In addition, the functional food may be prepared in a dosage form such as capsules, tablets, powders, liquid suspensions, pills and granules including kefir-derived lactic acid bacteria dead cells and grape seed powder.

In addition, the functional food may further include, as an active ingredient, not only kefir-derived lactic acid bacteria dead cells and grape seed powder, but also ingredients commonly added during food production.

Functional foods of the present invention include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonates used in carbonated beverages, and the like, and may contain pulp for the production of fruit juice or vegetable beverages.

The composition containing the grape seed powder and kefir-derived lactic acid bacteria dead cells of the present invention can also be utilized as a pharmaceutical composition for preventing or treating obesity.

The pharmaceutical composition according to the present invention contains kefir-derived lactic acid bacteria dead cells and grape seed powder as active ingredients, and may further include an appropriate carrier, excipient, or diluent according to a conventional method. The pharmaceutically acceptable carrier is commonly used in the formulation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, but are not limited thereto.

The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like in addition to the above components. Regarding suitable pharmaceutically acceptable carriers and formulations, it can be preferably formulated according to each component using the method disclosed in Remington's Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention may be administered orally or parenterally, and parenteral administration includes intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, and the like.

Formulations for oral administration include, for example, tablets, pills, hard, soft capsules, solutions, suspensions, emulsifiers, syrups, and granules. These formulations include diluents (e.g., lactose, dextrose, water) in addition to the active ingredients. Krose, mannitol, sorbitol, cellulose and/or glycine), lubricants (eg, silica, talc, stearic acid and magnesium or calcium salts thereof and/or polyethylene glycol). In addition, the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, in some cases starch, agar, alginic acid Or disintegrants or boiling mixtures and/or absorbents, colorants, flavors and sweeteners such as sodium salts thereof. The formulation can be prepared by conventional mixing, granulating or coating methods.

In addition, a typical formulation for parenteral administration is a formulation for injection, and as a solvent for the formulation for injection, water, Ringer's solution, isotonic physiological saline or suspension may be mentioned. The sterile fixed oil of the injectable preparation can be used as a solvent or suspension medium, and any non-irritating fixed oil including mono- and di-glycerides can be used for this purpose. In addition, the injectable formulation may use a fatty acid such as oleic acid.

The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type of disease, severity, and drug activity of the patient. , Sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. The composition according to the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with a conventional therapeutic agent, and may be administered single or multiple. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art.

Specifically, the effective amount of the composition according to the present invention may vary depending on the age, sex, and weight of the patient, and in general, 0.001 to 150 mg, preferably 0.01 to 100 mg per 1 kg of body weight, daily or every other day, or 1 to 1 day It can be administered in 3 divided doses. However, since it may increase or decrease according to the route of administration, sex, weight, age, etc., the dosage amount does not limit the scope of the present invention in any way.

Example

Hereinafter, the present invention will be described in more detail through examples. These examples are for illustrative purposes only, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not to be construed as being limited by these examples.

Experimental results of all examples were expressed as mean ± standard error (SEM), and statistical significance between each strain was verified using Staticstical Package for Social Sience (SPSS) version 21.0, and one-way analysis at a level of p<0.05. of variance (ANOVA) and Duncan's multiple range test.

Preparation Example 1: Preparation of heat-treated dead cells

Lactobacillus kepiri DH5 and Leukonostock mecenteroides LCM4 were incubated in MRS liquid medium at 30° C. for 24 hours.

Each cultured bacteria was centrifuged at 4°C for 5 minutes at 9,190×g, washed twice in sterile physiological saline and once in sterile distilled water, and heat-killed for 5 minutes at 95°C.

Samples of the two strains treated with dead bacteria were mixed well in a ratio of 1:1 and finally administered to the experimental mice through gavage administration.

Preparation Example 2: Grape seed powder preparation

Chardonnay grape seed powder was purchased and used from ApresVin Enterprises, Inc., USA.

The grape seed powder is made of wine using Chardonnay grapes, and the remaining by-products are cold-pressed to remove oil from the grape seeds, and the remaining products are hot air dried, and the skin part is removed using an air blow. Next, the remaining product is in the form of fine grained grape seed flour (GSF), which is filtered using a sieve having a size of 100 mesh (150 microns).

Experimental Example 1: Analysis of body weight change in mice according to diet

Obesity disease was induced by allowing 110 C57BL/6J mice to consume four types of diets as shown in Table 1 below for 9 weeks.

Ingredient (g/kg) High fat diet
(HFrD) HFrD +
2.5% GSF HFrD +
2.5% GSF +
HLAB HFrD +
Lactobacillus dead cells (HLAB) Lard fat 225.0 255 255 225.0 Soybean Oil 27 25 25 27 Cholesterol 0.8 0.8 0.8 0.8 Microcrystalline cellulose (MCC) 50 35.7 35.7 50 Casein 200 200 200 200 Corn Starch 91.2 82.5 82.5 91.2 Fructose 355 355 355 355 L-Cystein 3 3 3 3 Choline Bitartrate 3 3 3 3 Mineral Mix 35 35 35 35 Vitamin Mix 93G 10 10 10 10 GSF 0 25 25 0 Total Diet weight 1000.0 1000.0 1000.0 1000.0

Figure 1 (a) shows the total energy intake of the mice according to the type of diet, Figure 1 (b) shows the weight gain of the mice according to the type of diet.

In Figures 1 (a) and (b), although there was no significant difference in total energy intake between the experimental groups, it was confirmed that a significantly lower weight gain occurred in the group ingesting grape seed powder and/or lactic acid bacteria dead cells. I can.

In particular, the experimental group ingesting grape seed powder and kefir lactic acid bacteria together showed significantly lower weight gain compared to the experimental group ingesting them, indicating that grape seed powder and kefir lactic acid bacteria dead cells exert a synergistic effect.

Experimental Example 2: Changes in fat tissue weight according to diet

2 shows the change in the weight of adipose tissue according to the type of diet.

Although there was no significant difference in total energy intake according to each experimental group, a significant decrease in the weight of adipose tissue occurred in the group that ingested grape seed powder and/or lactic acid bacteria dead cells. The experimental group ingested together showed significantly lower adipose tissue weight reduction compared to the experimental group ingesting them.

Experimental Example 3: Adipose tissue size analysis

In Experimental Example 1, the adipose tissue was excised and fixed in 10% formalin, and then hematoxylin-eosin double staining (H&E stain) was performed for the mice that had been fed for 9 weeks. The results are shown in FIG. 3.

In Figure 3, it can be seen that the fat cell size of the experimental group in which the grape seed powder and the kefir-derived lactic acid bacteria dead cells were taken together was much smaller than the fat cell size of the experimental group that ingested them.

Experimental Example 4: Cholesterol Analysis

Triglyceride (TG, mg/dL) and total cholesterol (total cholesterol: TC, mg/dL) were measured using an automated biochemical analyzer (7020, HITACHI) from the liver tissue of the experimental mouse of Experimental Example 1 The results are shown in FIG. 4.

In FIG. 4, it can be seen that both TG and TC showed a significantly lower value than the average value of the experimental group in which the experimental mice ingested grape seed powder and kefir-derived lactic acid bacteria dead cells together.

Experimental Example 5: Analysis of gene expression

After RNA was isolated from the epididymal adipose tissue of the experimental mouse of Experimental Example 1, the expression level of the FASN (fatty acid synthase) gene was measured through RT-PCR. The measurement results are shown in FIG. 5.

As a result of the experiment, the expression level of FASN gene in the experimental group that ingested grape seed powder and kefir-derived lactic acid bacteria dead cells significantly decreased, and the FASN gene expression level in the experimental group that ingested grape seed powder and kefir-derived lactic acid bacteria dead cells was the most decreased Can be confirmed.

As described above, a specific part of the content of the present invention has been described in detail, and for those of ordinary skill in the art, this specific technology is only a preferred embodiment, and the scope of the present invention is not limited thereby It will be obvious. Accordingly, it will be said that the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims (15)

Kefir (Kefir) containing dead cells of lactic acid bacteria and grape seed powder as an active ingredient,
The dead cells of the kefir-derived lactic acid bacteria are contained in 0.1x10 ⁸ to 20x10 ⁸ lactic acid bacteria/grams of grape seed powder,
Functional food for improving obesity, wherein the dead cells are in the form of a water-soluble fraction of a suspension obtained by crushing kefir-derived lactic acid bacteria after heat treatment and killing.
The method of claim 1,
The kefir-derived lactic acid bacteria Lactobacillus kefiri ( Lactobacillus kefiri ), Leuconostoc mesenteroides ( Leuconostoc mesenteroides ), or a complex microorganism thereof, characterized in that, functional food for improving obesity.
The method of claim 2,
Functional food for improving obesity, characterized in that the complex cells contain Lactobacillus kepiri and Leukonostock mecenteroides in a concentration ratio of 5:1 to 1:5.
The method of claim 1,
Improvement of obesity, characterized in that the kefir-derived lactic acid bacteria are complex bacteria of Lactobacillus kefiri DH5 ( Lactobacillus kefiri DH5, accession number: KCCM11837P) and Leuconostoc mesenteroides LCM4 ( Leuconostoc mesenteroides LCM4, accession number: KCCM12117P) For functional food.
The method of claim 1,
The dead cells are functional foods for improving obesity, characterized in that the kefir-derived lactic acid bacteria are killed by heat treatment at 80°C or higher.
delete delete The method of claim 1,
Functional food for improving obesity, characterized in that it suppresses the expression of adipocyte-forming genes.
The method of claim 1,
Functional food for improving obesity, characterized in that the grape seed powder is a wine production by-product.
The method of claim 1,
Functional food for improving obesity, characterized in that the grape seed powder is made of grapes of Chardonnay (Chardonnay) varieties.
delete Including the dead cells of kefir-derived lactic acid bacteria and grape seed powder as active ingredients,
The dead cells of the kefir-derived lactic acid bacteria are contained in 0.1x10 ⁸ to 20x10 ⁸ lactic acid bacteria/grams of grape seed powder,
A pharmaceutical composition for preventing or treating obesity, wherein the dead cells are in the form of a water-soluble fraction of a suspension obtained by crushing kefir-derived lactic acid bacteria after heat treatment and killing.
The method of claim 12,
The kefir-derived lactic acid bacteria Lactobacillus kefiri ( Lactobacillus kefiri ), Leuconostoc mesenteroides ( Leuconostoc mesenteroides ), or a pharmaceutical composition for the prevention or treatment of obesity, characterized in that the compound thereof.
The method of claim 12,
The kefir-derived lactic acid bacteria are Lactobacillus kefiri DH5 ( Lactobacillus kefiri DH5, accession number: KCCM11837P) and Leuconostoc mesenteroides LCM4 ( Leuconostoc mesenteroides LCM4, accession number: KCCM12117P). Pharmaceutical composition for prophylaxis or treatment.
The method of claim 12,
The dead cells are characterized in that the killing of kefir-derived lactic acid bacteria by heat treatment at 80° C. or higher, a pharmaceutical composition for preventing or treating obesity.

Images